ATX MS 1467

Drug Profile

ATX MS 1467

Alternative Names: Antigen processing-independent epitopes - Apitope Technology; API 1,4,6,7; ATX-MS-01; ATX-MS-1467; M-2736; MSC2358825A

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Apitope Technology
  • Developer Apitope Technology; Merck Serono
  • Class Peptide vaccines; Peptides; Vaccines
  • Mechanism of Action Immunomodulators; Interleukin 10 stimulants; MHC class II gene modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 19 Oct 2016 ATX MS 1467 is available for licensing as of 17 Oct 2016.
  • 17 Oct 2016 Apitope Technology regains rights to ATX MS 1467 from Merck Serono
  • 15 May 2016 Merck completes a phase II trial in Multiple sclerosis (Intradermal, Injection) in Germany and Latvia (NCT01973491)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top